Reactive Oxygen Species in Mesenchymal Stem Cell Aging: Implication to Lung Diseases

Abstract EN

MSCs have become an emerging cell source with their immune modulation, high proliferation rate, and differentiation potential; indeed, they have been challenged in clinical trials.

Recently, it has shown that ROS play a dual role as both deleterious and beneficial species depending on their concentration in MSCs.

Various environmental stresses-induced excessive production of ROS triggers cellular senescence and abnormal differentiation on MSCs.

Moreover, MSCs have been suggested to participate in the treatment of ALI/ARDS and COPD as a major cause of high morbidity and mortality.

Therapeutic mechanisms of MSCs in the treatment of ARDS/COPD were focused on cell engraftment and paracrine action.

However, ROS-mediated therapeutic mechanisms of MSCs still remain largely unknown.

Here, we review the key factors associated with cell cycle and chromatin remodeling to accelerate or delay the MSC aging process.

In addition, the enhanced ROS production and its associated pathophysiological pathways will be discussed along with the MSC senescence process.

Furthermore, the present review highlights how the excessive amount of ROS-mediated oxidative stress might interfere with homeostasis of lungs and residual lung cells in the pathogenesis of ALI/ARDS and COPD.